$18.61 $0.51 (2.8%)

02:23 PM EDT on 05/29/20

Cellectis (NASDAQ:CLLS)

CAPS Rating: 5 out of 5

Current Price $18.61 Mkt Cap $734.7M
Open $18.34 P/E Ratio 0.00
Prev. Close $18.10 Div. (Yield) $0.00 (0.0%)
Daily Range $17.95 - $19.00 Volume 148,614
52-Wk Range $7.32 - $21.97 Avg. Daily Vol. 189,985

Caps

How do you think NASDAQ:CLLS will perform against the market?

Add Stock to CAPS Watchlist

All Players

45 Outperform
0 Underperform
 

All-Star Players

21 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CLLS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.44)
Submitted March 28, 2015

Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:CLLS VS S&P 500 (SPY)

NASDAQ:CLLS Summary

Fools bullish on NASDAQ:CLLS are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about CLLS.

Recs

0
Member Avatar odocoileus (55.41) Submitted: 1/30/2020 11:54:10 PM : Outperform Start Price: $16.30 NASDAQ:CLLS Score: +20.62

CAR-T is an amazing idea. Like all amazing ideas, the devil is in the details. While taking someone's cells, bio-engineering them to recognize cancer cells, and putting them back in the body is crazy smart, the expense and the body's reaction to that process are limiting the success of this technology. While allogenic T-cells do not come from the patient's body, they have some advantages. Namely, price, convenience, safety, and speed. Whether they are as effective remains to be seen, but any effectiveness at all may give allogenic T-cells an advantage for first line use. I like both CLLS and ATRA in this arena. While CLLS broke a lot of ground, ATRA eventually surpassed them. Success in either should draw interest and money into this arena and the share price may see tandem benefits.

Recs

3
Member Avatar zzlangerhans (99.44) Submitted: 3/28/2015 4:23:27 AM : Outperform Start Price: $36.00 NASDAQ:CLLS Score: -95.36

Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting European stocks in hot sectors before the rest of the market catches on and bids them up. In the case of Cellectis it's CAR-T. The potential advantage of Cellectis is that they are generating an allogeneic product that could be marketed "off-the-shelf" unlike the autologous therapeis being developed by Juno and Kite in the US. Cellectis hasn't even filed an IND for any of their CAR-T therapeutics so naturally they fall well into the speculative range of the biotech spectrum. Nevertheless, it's the hottest area in biotech right now so expect a lot of buoyancy in the segment until we see the first major setback or trial failure. We've built up quite a cushion of profits trading Cellectis so I imagine we'll continue to try and milk this cow a while longer.

Leaderboard

Find the members with the highest scoring picks in CLLS.

Score Leader

Playa14

Playa14 (< 20) Score: +76.04

The Score Leader is the player with the highest score across all their picks in CLLS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 < 20 10/17/2019 Outperform 5Y $10.46 +77.02% +0.89% +76.13 0 Comment
NextGenStock 23.94 9/11/2019 Outperform 5Y $12.41 +49.21% +0.69% +48.52 0 Comment
janaynay 65.57 1/28/2020 Outperform 5Y $16.11 +14.94% -7.13% +22.07 0 Comment
odocoileus 55.41 1/27/2020 Outperform 5Y $16.30 +13.57% -7.05% +20.62 1 Comment
LukeCrumb 96.32 2/11/2020 Outperform 5Y $17.47 +5.99% -10.21% +16.20 0 Comment
DeathStock 36.50 1/28/2019 Outperform 5Y $15.95 +16.09% +14.80% +1.29 0 Comment
gunda7907 < 20 1/17/2019 Outperform 5Y $16.90 +9.60% +15.40% -5.80 0 Comment
Reallynow222 97.51 11/19/2018 Outperform 5Y $21.63 -14.39% +10.94% -25.33 0 Comment
RossEnd 96.35 8/14/2017 Outperform 5Y $22.57 -17.96% +22.41% -40.37 0 Comment
portefeuille3 97.80 11/8/2017 Outperform 5Y $26.37 -29.78% +16.79% -46.57 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CLLS.